NDC-11 (Package) | NDC-9 (Product) (Ascending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
60429-0834-05 | 60429-0834 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 16, 2016 | In Use | ||
60429-0835-01 | 60429-0835 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 16, 2016 | Oct. 31, 2022 | In Use | |
60429-0835-05 | 60429-0835 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 16, 2016 | In Use | ||
60429-0909-60 | 60429-0909 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Sept. 28, 2016 | In Use | ||
60429-0910-30 | 60429-0910 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Sept. 28, 2016 | Feb. 28, 2023 | No Longer Used | |
60429-0925-90 | 60429-0925 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec. 30, 2016 | Dec. 31, 2020 | No Longer Used |
60429-0926-30 | 60429-0926 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec. 30, 2016 | In Use | |
60429-0935-30 | 60429-0935 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Sept. 20, 2016 | In Use | |
60429-0935-90 | 60429-0935 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Sept. 20, 2016 | In Use | |
60432-0140-50 | 60432-0140 | Cyclosporine | Cyclosporine | 100.0 mg/mL | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Feb. 9, 2005 | Feb. 5, 2012 | No Longer Used |
Found 10,000 results in 9 milliseconds — Export these results